Portland, OR -- (SBWIRE) -- 08/28/2017 -- Hydrocephalus or water on the brain is a condition that occurs when fluid builds up in the brain and leads to disturbance of cerebrospinal fluid (CSF) formation, flow, or absorption. This condition is also termed as hydrodynamic CSF disorder. Hydrocephalus Shunt is used to treat this disease, as the device relieves pressure on the brain caused by fluid accumulation.

Early buyers will receive 20% customization on this report.

The growth of the global hydrocephalus shunts market is driven by factors such as rise in the prevalence of brain & neurological disorders, increase in geriatric population, and rise in demand for minimally invasive surgeries.

However, issues regarding the infections caused by the use of hydrocephalus shunts and sometimes over drainage of cerebrospinal fluid restrain the market growth. Increased funding by government and private organizations across emerging economies for treatment of neurological disorders is expected to provide growth opportunities for the market growth.

The hydrocephalus shunt market is segmented on the basis of type, age group, and region. Based on type, the market is categorized into ventriculoperitoneal, ventriculoatrial, ventriculopleural, and lumboperitoneal shunts. By age group, it is classified into infants, toddlers, children, and adults. Geographically, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Request for Sample @ https://www.alliedmarketresearch.com/request-toc-and-sample/2682

The key players operating in the market include Johnson & Johnson, Medtronic plc, Christoph Miethke GmbH & Co. KG, Sophysa, B. Braun Melsungen AG, Integra LifeSciences Corporation, Tokibo Co., Ltd., and Spiegelberg GmbH & Co. KG